In addition, there is substantial evidence that the co-delivery of siRNA that shows specific binding to mRNA of the most commonly occurring KRAS missense mutations together with a chemical EGFR inhibitor may efficiently reduce mutant KRAS-induced effects and may contribute to overcoming resistance in the treatment of NSCLC [72,88–89]. Here, KRAS is linked to non-small cell lung carcinoma.